Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Short Interest Update

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 17,110 shares, a growth of 625.9% from the November 30th total of 2,357 shares. Based on an average trading volume of 54,221 shares, the short-interest ratio is currently 0.3 days. Based on an average trading volume of 54,221 shares, the short-interest ratio is currently 0.3 days.

Ono Pharmaceutical Price Performance

Shares of OTCMKTS OPHLY traded up $0.01 during trading on Wednesday, hitting $4.61. 6,469 shares of the company were exchanged, compared to its average volume of 247,374. Ono Pharmaceutical has a 1 year low of $3.21 and a 1 year high of $4.74. The firm’s fifty day moving average price is $4.31 and its 200 day moving average price is $3.92.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.